Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NE-100 is a **selective antagonist** of the sigma-1 receptor, one of the earliest such ligands reported and widely used as a pharmacological tool[1][3][7][9]. It exhibits **high affinity for the sigma-1 receptor** (Ki ≈ 1 nM) and markedly lower affinity for other receptors such as sigma-2, dopamine, and serotonin receptors[1][3]. NE-100 has been studied for its **potential antipsychotic activity without the typical motor side effects of neuroleptics**, and it shows neuroprotective and procognitive properties in preclinical models[3][5][7][9][15]. NE-100 is primarily used in research; it is not an approved pharmaceutical for clinical use and is known as a tool compound for investigating sigma-1 receptor physiology and pharmacology[1][3][5][9][13][15].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NE-100.